Controversies in BMT for Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Gascoyne, Randy D ^a   Moskowitz, Craig ^b   Shea, Thomas C ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; GENE EXPRESSION PROFILING; GERMINAL CENTER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAINTENANCE THERAPY; PATHOGENESIS; PLASMABLASTIC LYMPHOMA; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; RADIOIMMUNOTHERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871860177     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.024     Document Type: Article

References (23)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333:1540-1545.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
3. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989-1996.
4. Alousi AM, Saliba RM, Okoroji GJ, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008; 142:786-792.
5. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with AHSCT for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190.
6. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20: 451-458.
7. Cuccuini W, Josette Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119: 4619-4624.
8. Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011;35:183-187.
9. Vose JM, Carter SL, Burns LJ, et al. Randomized phase III trial of 131iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). Blood. 2011;118:661 [abstract].
10. Shimoni A, Avivi I, Rowe J, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118:4706-4714.
11. Krishnan A, Palmer J, Tsai NC, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiationebased conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant. 2012;18:441-450.
12. Majhail NS, Kirsten K, Ness KK, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Biol Blood Marrow Transplant. 2007;13: 1153-1159.
13. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
14. Carella A, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:3918-3924.
15. Lazarus H, Zhang MJ, Carreras J, et al. A comparison of HLAidentical sibling allogeneic versus AHSCT for diffuse large B-cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16:35-45.
16. Freytes C, Loberiza F, Rizzo J, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104: 3797-3803.
17. Roel JW, van Kampen RJ, Canals C, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group forBlood and Marrow Transplantation Registry. J Clin Oncol. 2011;29: 1342-1348.
18. Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20+ diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol. 2011;29: abstr 8004.
19. Carella A, de Souza C, Luminari S, et al. The prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens; a FIL/GEMOH retrospective study. Leuk Lymph. 2012.
20. Staudt L, Dunleavy K, Buggy L, et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood. 2011;118: abstr. 2716.
21. Advani A, Coiffier B, Czuczman M, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin'- s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085-2093.
22. Gordon L, Weller E, Armand P, et al. A phase II study of CT-011, an anti- PD-1 antibody, after AUSCT in recurrent/refractory DLBCL: first analysis of progression-free-survival (PFS), overall survival (Os) and toxicity. Ann Oncol. 2011;22(Suppl: 4):63 [abstract].
23. McCarthy P, Owzar K, Hofmeister C, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366: 1770-1781.